US HHS Nominee Becerra Treading Carefully On ‘March In’ Rights
Executive Summary
Past support for so-called ‘march in’ rights is a red flag for biopharma innovators, but after two days of confirmation hearings, industry can be somewhat reassured.
Topics
- Subjects
- Leadership
- Politics
- Intellectual Property
- Legal Issues
- Policy
- Pricing Debate
- Industries
- BioPharmaceutical
- Regions
- North America
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PS143887
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
PS143887
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.